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Evaluation of the Potential Role of Chelation
Therapy in Treatment of Low to Moderate
Lead Exposures
by J. Julian Chisolm, Jr.
Intheoverall long-termmanagementofleadpoisoning, chelationtherapycanhave short-term benefits; however,
these benefits must be accompanied by drastic reduction in environmental exposure to lead iftherapy is to
have any long-term benefit. This discussion is limited to calcium disodium ethylenediaminetetraacetate
(CaNa2EDTTA), the chelating agent that has been the mainstay oftreatment oflead poisoning for the past 38
years, and to meso-2,3-dimercaptosuccinic acid (DMSA), a new and promising oral chelating agent, which is
an orphan drugand iscurrentlyclassified as an investigational newdrugbytheU.S. FoodandDrugAdministra-
tion. With both drugs, multiple courses oftreatment will be needed ifany substantial reduction in body lead
burden is to be achieved. A major limitation ofCaNa2EDTA is the enormous diuresis ofzinc that it produces.
DMSA produces a comparable diuresis oflead, a greater decrease in blood lead, and has negligible influence
on the urinary losses ofzinc, copper, iron, and calcium. Limited experience to date in man has revealed no
significant adverse side effects ofDMSA. In animals, DMSA will promptly reduce the concentration of lead
in brain and kidney, in particular. By contrast, similar 5-day courses ofCaNa2EDTA do not produce any net
reduction in brain lead. This is important, as the brain is the critical organ ofthe adverse effects of lead in
children. Ifthe efficacy ofDMSA is to becomprehensivelyevaluatedethically inchildren, new and more sensitive
neurochemical, electrophysiologic, or other markers must be developed.
Introduction
Chelation therapy serves as a useful adjunct in the overall
management oflead toxicity. However, its full potential can
only be realized ifitis coordinated with prompt and substan-
tial reduction in environmental exposure to lead. The major
agents that have been used for over 35 years are calcium
disodium ethylenediaminetetraacetate (CaNa2EDTA) and
2,3-dimercapto-1-propanol (BAL). Although it is still consid-
ered an investigational drug by the United States Food and
DrugAdministration (FDA) when used to treat lead poison-
ing, D-penicillamine (PCA), which can be given orally, con-
tinues to be used primarily as a secondary or maintenance
drug. PCA is not highly effective and must be used with
great caution because it is associated with a variety of
adverse side effects, some of which, although rare, are
potentially very serious (erythema multiformi, Stevens-
Johnson syndrome, hemolytic-uremic syndrome). There is
no doubt that chelation therapy can drastically reduce the
mortality of acute lead encephalopathy and reverse the
clinical and biochemical effects ofacutely symptomatic lead
poisoning. During the prechelation therapy days, the mortal-
ity of severe acute encephalopathy was 66% (1). Today, with
combined BAL-CaNa2EDTA therapy, the mortality is prob-
ably no more than 1 to 2% (2). The rapidity with which
the diagnosis is made probably is the critical factor. Even
so, it is not clear that chelation therapy ameliorates to any
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significant degree the sequellae ofthe severe forms of the
disease (3).
What, then, is the role of chelation therapy in the treat-
ment of asymptomatic children with low to moderate in-
creases in body lead burden? This discussion willbe limited
to CaNa2EDTA, the principal drug used to treat lead tox-
icity for the past 38 years, and to meso-2,3-dimercapto-
succinic acid (DMSA), a most promising new oral chelating
agent, which is an orphan drug and is currently classified
by the FDA as an investigational new drug. Althoughlimited
and sometimes conflicting, experimental data suggest that
supplementation with zinc, large oral doses ofascorbic acid,
or thiamine given by injection may potentiate the beneficial
effects of either CaNa2EDTA or DMSA (4-6); these will
not be discussed. A recent pilot study in children indicates
that2,3-dimercaptopropane-1-sulfonate (DMPS) may signifi-
cantly increase the urinary loss ofcopper and is inferior to
both CaNa2EDTA (7) and DMSA in terms of the reduction
in blood lead concentration (PbB) and the diuresis of lead
induced. Furthermore, dermatological reactions, including
at least one case of Stevens-Johnson syndrome, have
recently occurred in patients receiving the drug for more
than 5 successive days, so DMPS does not merit further
consideration.
CaNa2EDTA: Human Studies
It has been standard clinicalpractice for a number ofyears
to administer CaNa2EDTAparenteraily for 5 days. FollowingJ. J. CHISOLM, JR.
a 2- to 4-day rest period, a second 5-day course may be
administered. Limitation of courses to 5 successive days
is based upon clinical experience inthe 1950s, which showed
that longer periods of continuous administration at higher
doses than used today were nephrotoxic and were some-
times associated with fatalities due to renal failure (8).
Figure 1 shows changes in PbB concentration in a child
in relation to intermittent 5-day courses of CaNa2EDTA.
These data are probably representative ofthe way in which
the drug is widely used in children in the U.S. today. The
childis treated for 5 days, senthome, and recalled in a month
or so, perhaps treated again, and so on. In this particular
case, the physicians treating the child became frustrated and
referred the child to me for more intensive chelation therapy.
We are fortunate in Baltimore to have two pediatric inter-
mediate care facilities in which children can be kept fortreat-
ment for longer periods of time than they can in general
hospitals. Because of experimental evidence that CaNa2
EDTA and PCA may increase absorption and retention of
any lead in the gut, it is prudent to administer these drugs
in a clean environment (9). As the exposure to lead in dete-
riorated paint had finally been corrected, the house was
vacuumed thoroughly with a high efficiency particle accum-
ulator (HEPA) vacuum, whereupon the child was discharged
(Fig. 1). An example of serial changes in PbB in a child
receiving intensive chelation therapy initially are shown in
Figure 2.
Other changes that are uniformly associated with 5-day
courses of CaNa2EDTA are summarized in Table 1. PbB
concentration decreases to 55 to 60% ofthe pretreatment
value at the end of the 5-day course, but within 4 days re-
bounds in hospital by an average of5 jtg lead/dL in this par-
ticular group.' Serum zinc decreases within 48 hr to 70%
ofthe pretreatment value, but rebounds within 3 to 4 days
after of treatment as shown in Table 1 on day 9. Alkaline
phosphatase, a zinc-dependent enzyme, decreases signifi-
cantly, but quicklyrebounds to the pretreatment value. Like-
wise, serum transaminases increase, but return to the
pretreatment value within 3 to 4 days after treatment. The
decrease in serum zinc is associated with the 17- to 20-fold
increase in urinary loss of zinc. In the absence of therapy,
young children excrete an average ofabout 200/tg zinc/day
or 1 mg/5 days in urine. During 5-day courses of v
CaNa2EDTA, we have observed losses in children of 12 to
30 mg of zinc (10) and losses in adults of 60 to 100 mg of
zinc in urine in 5 days. CaNa2EDTA, a nonspecific metal
binding agent, also is associated withincreases in the urinary
losses ofiron, manganese, copper, and cadmium. The losses
of these other metals are small. It is probable that much
of the toxicity of CaNa2EDTA is associated with the mobili-
zation of zinc.
'These studies were approved by theJoint Committee on Clinical Inves-
tigation of theJohns Hopkins Medical Institutions. Prior informed written
parental consent was obtained.
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FIGURE 1. Changes in PbB concentration in relation to intermittent 5-day courses ofCaNa2EDTA. Serial changes in PbB (mcgldL) in a 25-month-old child are
plotted on the ordinate against time (days) over a period of 17 months on the abscissa. Solid lines show changes during chelation therapy; the dashed lines
show changes while not receiving therapy. Dosage of CaNa2EDTA (with added procaine, 0.5% final concentration) was 1000 mglm2/24 hr given in divided
dose every 12 hr by deep intramuscular injection for 5 days. The post-treatment PbB concentrations within 24 hr after the first three courses were 57,
58, and 58%, respectively, ofthe pretreatment values as shown at the left ofthe figure. Twelve months after the first course, the child received two courses
ofCaNa2EDTA in the same dosage separated by 4 days with the result that PbB decreased from 60 to 28 mcg/dL. The child received oral PCA daily (500
mg/m2/dose) supplemented by CaNa?EDTA IM (500 mg/m2/dose) given on alternate days, which sustained the improvement. Rebound in PbB peaked 2
months later and then decreased spontaneously. Free erythrocyte protoporphyrin concentrations (not shown) decreased steadily throughout the 17-month
period of observation.
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FIGURE 2. Changes in PbB concentration during and after intensive chelation therapy. Serial changes in PbB (mcg/dL) in a 33-month-old child are plotted as
in Figure 1 over a period of 17 months. Initially, the child received CaNa2EDTA (1000 mg/m2/24 hr given in divided dose every 6 hr IM) for 5 days. During
the first 3 days, BAL (333 mg/m2/24 hr in divided dose every 6 hrTM) was also given. After 3-day rest periods, second and third 5-day courses ofCaNa2EDTA
in the above dosage were also given. Following this, child was placed on maintenance therapy (PCA 500 mg/r2! dose each day, per os and CaNa,EDTA,
500 mg/m2/dose IM on alternate days). After 6 weeks, the child was discharged to a home free oflead-based paints, where she remained throughout the
rest of the 17-month period of observation. The expected rebound in PbB was noted 6 weeks treatment. After this, PbB spontaneously decreased but
had not yet reached an acceptable level. Free erythrocyte protoporphyrin (not shown) steadily decreased throughout the entire period.
Table 1. Changes in mean blood lead, serum zinc, serum
transaminases,a and serum alkaline phosphatase during
and after 5-day course of CaNa2 EDTA in 10 children.
Day
Parameter 0 2 5 9
Blood lead, mcg/dL 49.75 - 26.55 31.25
Serum zinc, mcg/dL 87.0 61.0 62.0 110.0
ALT, U/L 25.7 - 43.4 28.0
AST, U/L 35.6 - 59.0 32.2
Alkaline phosphatase, U/L 272.0 - 185.0 260.0
aSenum transaminases: ALT, serum alanine aminotransferase; AST, serum
aspartate aminotransferase.
The cumulative excretion of lead in urine is essentially
linear in each child during the 5 days of therapy, although
total output varies widely (10). The portion of the body
burden of lead, which is available for chelation by
CaNa2EDTA, can be estimated by compartmental analysis
as described by Piotrowski (11). In this procedure, linear
regression analysis oflog-transformed data on daily urinary
excretion ofleadduringtherapy is used to estimate the half-
time and rate constant (k) for each child. Ae is the total
amount of lead excreted in urine during a 5-day course of
therapy. These data can then be used to calculate the size
of the prechelation lead pool (A), according to the formula
Ao = AI(-e-kt). This procedure assumes a one-compart-
ment, open model, whichprobably underestimates the pool,
as there may be transfers oflead between pools during the
5 days. Furthermore, the kinetic studies of Rabinowitz et
al. (12) indicate that a more complex model is required for
lead.
Table 2 summarizes data for 18 preschool-aged children
in whom we have obtained essentially complete 5-day col-
lections of urine.' In this group, mean pretreatment blood
lead was 55 yg lead/dL whole blood, while the mean post-
treatment PbB obtained 12 hr after the last dose of
CaNa2EDTA was 33 lsg lead/dL, or 60% of the pretreat-
ment level. Compartmental analysis revealed a wide range
in the estimated pretreatment chelatable lead pools (A0),
while on average, 62% ofthe estimated pool was excreted
during the 5-day course. In theory, one would want a
chelating agent specific for lead that could be safely ad-
ministered until the diuresis oflead terminated. This is not
possible with CaNa2EDTA for reasons of safety. Also, the
data help to explain the rebound in PbB immediately after
treatment, which presumably is due to internal redistribu-
tion of lead. Even after multiple courses of CaNa2EDTA,
body lead stores are likely to remain elevated (13).
DMSA: Human Studies
DMSA was first synthesized by Friedheim and DaSilva
in 1954. The antimony chelate of DMSA was initially used
for the treatment ofschistosomiasis (14). The Chinese first
reported the use ofDMSA as an antidote forpoisoning due
69J. J. CHISOLM, JR.
Table 2. Estimates of prechelation lead pool by compartmental
analysis in 18 children treated 5 days with CaNa2EDTA.a
Patient
number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
Pretreatment
PbB, mcg/dL
52
51
70
42
46
60
54
53
97
41
47
60
59
37
56
49
48
52
Compartmental analysis,b mcg lead
A,
4678
3124
2346
1858
1345
4840
1817
1799
4998
2568
1954
5136
3974
5165
4056
2064
2307
2126
2490
1720
1710
1230
850
3610
1760
1770
3150
1700
826
2172
2003
2185
1825
1410
1454
1218
A4 as % ofA,
53
55
73
66
63
75
97
98
63
66
42
42
50
42
45
68
63
57
Mean 62
aDosage of CaNa2EDTA = 1000 mg/m2 day in divided dose every 12 hr,
intramuscular.
bCalculations: A,=(A/ -e-k' where A, = prechelation lead pool, A, =
total lead excreted in 5 days, and k = rate constant.
to mercury and lead (15). Within the past decade, substan-
tial interest in DMSA as a promising oral chelating agent
for the treatment of lead toxicity has developed. Its phar-
macology has been reviewed by Aposhian (16) and Aaseth
(17). DMSA has a substantially wider therapeutic index than
other agents used to treat leadtoxicity. Graziano et al. have
given DMSA orally for 5 days to both adults (1) and children
(19) and found that it is well tolerated; it reduces PbB to
nearly 25 to 30% ofthe pretreatment value; it is associated
with rapid reversal of the biochemical indicators of lead's
adverse effects on heme synthesis; and it induces a diuresis
oflead nearly comparable to that associated with administra-
tion of CaNa2EDTA. Efficacy is dose-related. Oral dosage
of 30 ,ug/kg of body weight per day in adults or 1050
mglm2/day in children given in divided dose is the most
effective dose (Fig. 3). No significant increase in urinary loss
of zinc, copper, iron, or calcium is observed. To date, the
oniy changes noted in humans have been occasional and tran-
sient increases in serum transaminases (aspartate amino-
transferase [AST] and alanine aminotransferase [ALT]). As
with CaNa2EDTA, blood lead concentration rather promptly
rebounds immediately following treatment.
In our clinic, we have essentially complete 24-hr urine
collections made on the Pediatric Clinical Research Unit of
theJohns Hopkins Hospitalin fourchildren. Analysis ofthe
data indicates that, as with CaNa2EDTA, the cumulative
5-day excretion of lead during treatment with DMSA is
essentially linear with dose.1 The total amounts of lead
excreted during 5 days (A) are well within the range that
has previously been observed in children with comparable
pretreatment PbB concentrations who were treated with
CaNa2EDTA in a dose of 1000 mg/m2/day given in divided
dose every 12 hrby deepintramuscular injection (with added
procaine).
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FIGURE 3. Serial changes in PbB during and after 5-day courses oforal DMSA
and parenteral CaNa2EDTA in children. Groups are as follows: (q) DMSA
350mgWm2day; (O) DMSA 700mg&m2day; (A) DMSA 1050 mg&m2day;
(0) CaNa2EDTA 1000 mg/m2/day. The 1050 mg/m2/day dose of DMSA
is the most effective inreducingPbB; however, inall groups PbB rebounds
following therapy. Repr-oduced by permission from Graziano et al. (19).
Table 3. Estimates of prechelation lead pool by compartmental
analysis during first 5 days of oral DMSA therapy.a
Patient Pretreatment Compartmental analysis,b mcg lead
number PbB, mcg/dL A, A, A, as % of A,
1 43 1678 844 51
2 42 1450 855 59
3 70 6237 4057 65
4 60 5636 3657 65
aDosage of DMSA = 1050 mglm2/day per os in divided dose.
bCalculation: A, = A41(1 -e-k) where A, = prechelation lead pool, A =
total lead excreted in 5 days, and k = rate constant.
Compartmental analysis of the data (Table 3) tentatively
suggests that the percentage ofthe estimated prechelation
lead pool excreted in 5 days is similar to that observed with
CaNa2EDTA. This, of course, is not to say that the pools
of lead available for chelation by CaNa2EDTA and DMSA
are identical, although this very limited data base suggests
that they may be ofcomparable magnitude. At the present
time, studies are in progress in various centers to deter-
mine whether longer courses of DMSA may be both safe
and more efficacious than 5-day courses.
Figure 4 shows serial blood lead data in fourchildren who
have received five 10-day courses of oral DMSA in the
Pediatric Clinical Research Unit oftheJohns Hopkins Hos-
pital. These studies were carried out on anin-patient basis
to preclude the possibility ofexcessive ingestion oflead that
might occur on an out-patient basis.' During the first 5
days, all received 1050 mg DMSA/m2/day in three divided
doses. During the second five days, dosage was reduced
to 350 mg DMSA/m2 day given in divided dose.
Increase in PbB within a few days after treatment is
observed in all; however, more importantly, those with pre-
treatment PbB concentrations of52, 60, and 70,g/dL show
increasing blood lead concentration while on therapy dur-
ing the second 5 days when the lower dose was given. The
child with the initial pretreatment PbB of 70 Ag received
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FIGURE 4. Changes in PbB concentration during and after 10-day courses of oral DMSA therapy. PbB (mcg/dL) values are plotted on the ordinate against time
(days) on the abscissa. the solid portion of each line shows changes in serial PbB concentration while on therapy in hospital; the dashed portion of each
line shows post-treatment changes after discharge to dwellings thought not to contain lead paint hazards. Data are shown for four children, one of whom
received a second 10-day course when PbB rebounded to 52 mcg/dL 2.5 weeks after the first course oftherapy. During the first 5 days of treatment, DMSA
was given orally in divided dose (1050 mg/m2/day) and then reduced to 350 mglm2/day during days 6 to 10. Note that PbB increased during therapy when
the dosage was reduced to 350 mg/m2/day in the children with pretreatment PbB concentrations of 70, 60, and 52 mcg/dL, respectively.
a second 10-day course oftherapy when his PbB rebound-
ed to 52 /tg/dL whole blood within 2.5 weeks after the first
course. It seems clear, then, that some adjustment in dosage
will have to be made; indeed, Graziano (personal commu-
nication) has found that an initial 5-day regimen at 1050
mg/m2/day followed by reduction of dosage to 700 mg/m2/
day will prevent a rise in PbB during an additional 2 weeks
oftherapy at this dose. Itisclear, then, that repeated courses
of oral DMSA will be needed in many if not all cases. The
determining factor is probably the magnitude of the body
lead burden prior to therapy.
Recent Experimental Studies
According to Aaseth (17), "Enhanced excretion induced
by a drug is meaningless from a therapeutic point of view
ifit is not parallelled by a decrease of the metal concentra-
tion in the critical organ." Recent experimental and clinical
studies provide compelling evidence that the developing brain
is the critical organ for the toxic effects oflead in the fetus
and young child (20). In the absence of a sensitive biological
marker that could be ethically used in children to assess
the effects of chelating agents on central nervous system
function in young asymptomatic children with low to mod-
erately increased body lead burdens, we must turn to experi-
mental animals.
Recently, investigators have turned more and more to
chronic, low-level lead exposure, which probably provides
a better animal model than past studies in which acute treat-
ment with high doses of lead followed by high doses of
chelating agents were used. It has long been known that
the administration of chelating agents poses the risk of
translocation of metals from one tissue site to another and
from one organ to another. For example, experimental ad-
ministration oflead together with disulfiram not only results
in much greater uptake of lead by brain than dosing with
lead alone, but also intensifies the neurochemical distur-
bances attributable to lead (21).
Cory-Slechta et al. (22) have administered CaNa2EDTA
to chronically poisoned rats over a 5-day period, sacrificing
animals for tissue analyses after 1, 2, 3, 4, or 5 days ofdrug
administration. As in humans, decrease in PbB concentra-
tion and abrisk diuresis oflead were observed. On the other
hand, liver lead increased for 3 days and then decreased.
More importantly, particularly at the higher dose used, there
was a sharp increase in the concentration of lead in brain
after a single injection (Fig. 5). In agreement with the studies
of Goyer and Cherain (4) and Dhawan et al. (5), no net
decrease in brain lead was observed after 5 days. Goldstein
and colleagues (23) earlier found that the uptake and reten-
tion of lead by brain in immature rats was greater than in
their mothers and that brain lead was not affected by EDTA.
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FIGURE 5. Brain lead (mcg/g wet weight) as a function of the number of 75 mg/kg (eft panel) or 150 mg/kg! (right panel) of CaNa2EDTA injections in rats
chronically exposed to lead prior to treatment. Note the sharp increase in brain lead after a single injection of CaNa2EDTA, particularly after 150 mg/kg
dose. No net reduction in brain lead is observed in either group after five daily injections of CaNa2EDTA. Reproduced by permission from Cory-Slechta
et al. (22).
In man, a sharp and significant increase in plasma lead, peak-
ing 1.5 hr after injection of CaNa2EDTA, has again been
demonstrated recently (24). Araki et al. (25) also found in
lead workers that the amount oflead excreted in urine under
the influence of CaNa2EDTA was significantly correlated
with PbB and erythrocyte lead, but not with plasma lead.
Taken together, these studies call for a reappraisal of the
role of CaNa2EDTA, particularly its diagnositc use (26).
Cory-Slechta (27) has also carried out a similar study ad-
ministering DMSAby intraperitoneal injection to rats. Under
these conditions, prompt reduction in brain lead was observ-
ed (Fig. 6) in agreement with the earlier report of Graziano
et al. (28). Kidney lead was also substantially reduced. The
limited experimental data do not provide a clear indication
ofthe influence of DMSA on bone lead. Cory-Slechta (27)
also analyzed the tissues ofanimals sacrificed 4 months after
a 5-day course ofDMSA and found that internal redistribu-
tion oflead had occurred and that the concentrations oflead
in the various tissues did not differ significantly from those
found in control animals (Fig. 7). Only Bankowska and Hine
(6), who administered intermittent chelation therapy to
mature rats over a 6-week period, have reported a signifi-
cant reduction in brain lead in association with 6 weeks of
treatment with either CaNa2EDTA or DMSA.
Efficacy of Chelation Therapy Alone
The available clinical and experimental data indicate that
oral therapy with DMSA is most promising for the treat-
mentoflow to moderate increases inbody lead burden. Most
importantly, studies in animals indicate that short courses
of DMSA signfificantly reduce brain lead, while CaNa2EDTA
does not. DMSA may also be more effective in reducing
kidney lead. It is, however, clear that long-term therapy will
be required ifpossible long-term benefits are to be realized.
The influence of DMSA on essential metals has not been
extensively studied. Most ofthe experimental data are based
on studies in mature rodents. Future studies employing
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FIGURE 6. Changes in brain lead (mcg/g of wet weight) after serial daily injec-
tions (IP) ofDMSA in rats chronically exposed to lead prior to treatment.
A highly significant reduction in brain lead is observed after the fourth injec-
tion at both dosages. Reproduced by permission from Cory-Slechta (27).
immature rodents would be most helpful in delineating age-
related differences in their responses to DMSA and its influ-
ence on the neurochemical and neurobehavioral effects of
lead. Are there points at which some ofthese effects might
be reversible by treatment with DMSA?
Ofparticular interest to clinicians is the report ofKapoor
et al. (29). These workers administered DMSA orally to
rats immediately following oral lead dosing and found that
absorption and whole-body retention oflead was significantly
reduced in comparison with controls. The possible enhance-
ment of absorption and retention of lead has long been a
serious cinical concern with regard to other chelating agents.
Even so, these authors point out the technical difficulties
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FIGURE 7. Tissue lead (mcg/g concentrations bone, dry weight; all other
tissues, wet weights) of individual lead-exposed animals that received a
daily IP injection of saline (controls) or 50 mg/kg of DMSA once a day
for 5 days and were sacrificed 4 months later. Eachpoint represents avalue
for an individual animal. Statistical analysis (t-test) showed no significant
differences between controls and treated animals for any tissue. Reproduced
by permission from Cory-Slechta (27).
ofsuch experiments and note thatchelation is not a substitute
for control of exposure to lead. A major limitation of
CaNa2EDTA is its ability to mobilize significant amounts of
zinc (and possibly manganese). Limited data suggest that
depletion of zinc can be blunted when ZnCaEDTA is given
to rats (30). Whether this would prevent some ofthe other
unwanted effects of CaNa2EDTA is not known.
In comparison with CaNa2EDTA, DMSA appears to pro-
duce a comparable diuresis of lead and a greater effect on
PbB in humans. In children and adults increases in the
urinary loss of zinc, copper, iron, and calcium with DMSA
are quite small and probably clinically insignificant. With
regard to CaNa2EDTA, its practical disadvantage is the fact
that it must be administered parenterally, and its biological
disadvantage is the substantial reduction in plasma zinc and
the enormous diuresis ofzinc associated with its administra-
tion. It also causes statistically significant increases in the
urinary losses of manganese and iron. For these reasons,
it does not appear to be an ideal agent for the treatment
of modest increases in body lead burden.
The possibility that DMSA might reduce brain lead in
children, in particular, is intriguing. To assess this possibility,
new and more sensitive neurochemical, electrophysiologic,
or other biologic markers of central nervous system func-
tion are needed. At the present time, the most common
markers ofbiologic effect oflead are those associated with
heme synthesis. Clinical experience to date also indicates
that early intervention before a very substantial increase in
body lead burden has occurred is more likely to be associated
with a favorable outcome.
Post-Treatment Lead Exposure
The potential benefits of even repeated courses ofchela-
tion therapy will be largely vitiated unless post-treatment
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FIGURE 8. Geometric mean blood lead concentrations before and after therapy
according to housing classification. Numbers in each housing group are
shownin parentheses. Serial PbB dataduringthe first 12 months offollow-up
are shown as their antilogarithms. After treatment, groups I, IIa, and IV
eitherresided inorcontinued to visitoldhousinginwhichleadpainthazards
had been only partially abated according to local regulations at the time
(priortoJuly 1987). Group IIb resided exclusively inlead-free public hous-
ing after treatment, while group III was relocated in totally gutted and
rehabilitatedhousing. PbB differedsignificantly betweengroup Ilb andgroups
I, Ila, and IV (p < 0.001). Reproduced by permission from Chisohm et
al. (31).
exposure to environmental lead is drastically reduced. From
the practical point ofview, particularly in regard to children
exposed to lead primarily in old, deteriorated residential
paint, reduction in exposure is not readily achieved. Figure
8 shows serial blood lead data for 184 children during the
first 12 months following therapy in hospital (31). Children
are grouped according to the type ofhousing to which they
returned. All had a PbB > 50 ,tg/dL prior to treatment
andwere treated foran average of52 days in hospital. Those
returning to or visiting old housing that had been abated
according to localordinances in Baltimore atthe time showed
average PbB of38 ,ug/dL or greater. Only those discharged
to public orgut-rehabiJitiated housing showed somewhat bet-
ter, but still not acceptable, results, even2 to 2.5 years after
therapy. Again, given the newer evidence on the subtle,
adverse effects oflead on mental development in children,
a highly favorable outcome would not be expected. Newer
and far more stringent regulations for the abatement oflead
paint hazards have recently been introduced by the City of
Baltimore and the State ofMaryland. These regulations place
greatest emphasis on reduction of interior household dust
lead. It is hoped that these regulations, in combination with
recent reductions in exposure to lead in air and food, may
lead to a better outcome in coming decades.
Summary
In summary, DMSAis a mostpromisingnew oralchelating
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agent for the treatment oflow and moderate lead exposures.
Eirly studies indicate that short courses are safe and
efficacious. On the other hand, any substantial reduction in
body lead burden will probably require administration of
DMSA over a period ofat least several months either con-
tinuously or intermittently. The safety and efficacy oflong-
term treatment require further study. Early intervention is
likely to be much more efficacious than late intervention
during the chronic phase ofplumbism. New biologic markers
will be needed to assess its efficacy with regard to the
developing central nervous system in young children. For
beneficial effects over the long run, drastic reduction in
environmental exposure to lead is essential.
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